Split History
ETFs Holding COGT »    COGT Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cogent Biosciences is a biotechnology company focused on developing therapies for genetically defined diseases. Co.'s approach is to design therapies that treat the underlying cause of disease and improve the lives of patients. Co.'s main program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. Bezuclastinib is a highly selective KIT inhibitor with the potential to provide a new treatment option for these patient populations. In addition, Co.'s research team is developing a portfolio of targeted therapies to help patients fighting serious, genetically driven diseases. According to our COGT split history records, Cogent Biosciences has had 1 split.
COGT split history picture
Cogent Biosciences (COGT) has 1 split in our COGT split history database. The split for COGT took place on November 09, 2020. This was a 1 for 4 reverse split, meaning for each 4 shares of COGT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.

When a company such as Cogent Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the COGT split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cogent Biosciences shares, starting with a $10,000 purchase of COGT, presented on a split-history-adjusted basis factoring in the complete COGT split history. COGT split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/02/2018
End date: 09/26/2022
Start price/share: $43.00
End price/share: $14.39
Dividends collected/share: $0.00
Total return: -66.53%
Average Annual Total Return: -21.65%
Starting investment: $10,000.00
Ending investment: $3,345.66
Years: 4.49
Date Ratio
11/09/20201 for 4
COGT is categorized under the Industrials sector; below are some other companies in the same sector that also have a history of stock splits:

CP Split History
CPRT Split History
CPST Split History
CR Split History
CREG Split History
CRRC Split History
CSS Split History
CSX Split History
CTAS Split History
CTS Split History

Email EnvelopeFree COGT Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Avenue Therapeutics, Inc. (ATXI)
Annaly Capital Management, Inc. (NLY)
CohBar, Inc. (CWBR)
TOP Ships Inc. (TOPS)
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Nabriva Therapeutics plc (NBRV)
NeuroBo Pharmaceuticals, Inc. (NRBO)
First Wave BioPharma, Inc. (FWBI)
Palatin Technologies, Inc. (PTIN)
TD Holdings, Inc. (GLG )
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

COGT Insider Buying

COGT Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.